[HTML][HTML] Investigational drug treatments for triple-negative breast cancer
C Damaskos, N Garmpis, A Garmpi… - Journal of personalized …, 2021 - mdpi.com
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) and
accounts for 10–20% of cases. Due to the lack of expression of several receptors, hormone …
accounts for 10–20% of cases. Due to the lack of expression of several receptors, hormone …
Advances in targeted therapies for triple-negative breast cancer
KE McCann, SA Hurvitz, N McAndrew - Drugs, 2019 - Springer
While the outcomes for patients diagnosed with hormone receptor positive (HR+) and/or
human epidermal growth factor receptor 2-positive (HER2+) breast cancers have continued …
human epidermal growth factor receptor 2-positive (HER2+) breast cancers have continued …
Triple-negative breast cancer: The progress of targeted therapies and future tendencies
C Damaskos, A Garmpi, K Nikolettos… - Anticancer …, 2019 - ar.iiarjournals.org
Triple-negative breast cancer (TNBC) is characterized by a lack of expression of estrogen
receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 …
receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 …
Emerging therapeutics for patients with triple-negative breast cancer
Purpose of review Triple negative breast cancer (TNBC) accounts for approximately 10–
15% of all breast cancers and it is associated with a poor prognosis. However, recent new …
15% of all breast cancers and it is associated with a poor prognosis. However, recent new …
[HTML][HTML] Targeted therapeutic strategies for triple-negative breast cancer
Y Li, Z Zhan, X Yin, S Fu, X Deng - Frontiers in oncology, 2021 - frontiersin.org
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer,
which is characterized by the absence of estrogen receptor (ER) and progesterone receptor …
which is characterized by the absence of estrogen receptor (ER) and progesterone receptor …
[HTML][HTML] Current landscape of personalized clinical treatments for triple-negative breast cancer
J Zhang, Y Xia, X Zhou, H Yu, Y Tan, Y Du… - Frontiers in …, 2022 - frontiersin.org
Triple-negative breast cancer (TNBC) is a highly malignant subtype of breast cancer (BC)
with vicious behaviors. TNBC is usually associated with relatively poor clinical outcomes …
with vicious behaviors. TNBC is usually associated with relatively poor clinical outcomes …
Biology and management of patients with triple-negative breast cancer
P Sharma - The oncologist, 2016 - academic.oup.com
Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers and is
associated with poor long-term outcomes compared with other breast cancer subtypes …
associated with poor long-term outcomes compared with other breast cancer subtypes …
Update on the treatment of early-stage triple-negative breast cancer
P Sharma - Current treatment options in oncology, 2018 - Springer
Opinion statement Triple-negative breast cancer (TNBC) accounts for 15% of all breast
cancers and is associated with poor long-term outcomes compared to other breast cancer …
cancers and is associated with poor long-term outcomes compared to other breast cancer …
[HTML][HTML] Recent advances in targeted strategies for triple-negative breast cancer
S Zhu, Y Wu, B Song, M Yi, Y Yan, Q Mei… - Journal of Hematology & …, 2023 - Springer
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer,
negatively expresses estrogen receptor, progesterone receptor, and the human epidermal …
negatively expresses estrogen receptor, progesterone receptor, and the human epidermal …
[PDF][PDF] Promising therapeutic options in triple-negative breast cancer
A Bilici, C Arslan, K Altundag - J BUON, 2012 - jbuon.com
Triple-negative breast cancer (TNBC) has a greater risk of recurrence despite more
aggressive therapy even in lowrisk category. TNBC is high grade, hormone receptor and …
aggressive therapy even in lowrisk category. TNBC is high grade, hormone receptor and …